Premium
What can we learn in drug allergy management from World Health Organization's international classifications?
Author(s) -
Tanno L. K.,
Torres M. J.,
Castells M.,
Demoly P.
Publication year - 2018
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13335
Subject(s) - epidemiology , public health , drug allergy , medicine , health care , psychological intervention , intensive care medicine , drug , nursing , political science , psychiatry , pathology , law
Drug hypersensitivity reactions ( DHR s) represent growing health problem worldwide, affecting more than 7% of the general population, and represent an important public health problem. However, knowledge in DHR s morbidity and mortality epidemiological data is still not optimal and international comparable standards remain poorly accessed. Institutional databases worldwide increasingly use the WHO International Classification of Diseases ( ICD ) system to classify diagnoses, health services utilization, and death data. The misclassification of disorders in the ICD system contributes to a lack of ascertainment and recognition of their importance for healthcare planning and resource allocation. It also hampers clinical practice and prevention actions. To further inform the allergy community and to ensure that the revision process is transparent as advised in the WHO ICD ‐11 revision agenda, we report the advances and use of the pioneering “Drug hypersensitivity” subsection of ICD ‐11 and implementation in the WHO International Classification of Health Interventions ( ICHI ). The new classification addressed to DHR s will enable the collection of more accurate epidemiological data to support quality management of patients with drug allergies and better facilitate healthcare planning and decision‐making and public health measures to prevent and reduce the morbidity and mortality attributable to DHR s.